Clinical trial
Impact of Dermatological Toxicities on Quality of Life in Patients With Early Breast Cancer Exposed to Adjuvant Endocrine Therapy: a Real-world Cross-sectional Study. BCARE (Breast Cancer Adjuvant Real-world Evaluation of Dermatological Adverse Events)
NCT06690489 is registered in ClinicalTrials.gov with Pierre Fabre Medicament as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Impact of Dermatological Toxicities on Quality of Life in Patients With Early Breast Cancer Exposed to Adjuvant Endocrine Therapy: a Real-world Cross-sectional Study. BCARE (Breast Cancer Adjuvant Real-world Evaluation of Dermatological Adverse Events)
- Lead sponsor
- Pierre Fabre Medicament
- Phase
- Observational
- Overall status
- Completed
- Start date
- November 22, 2024
- Completion date
- November 26, 2025
- Enrollment
- 155 (actual)
- Sites
- 9
Conditions
As the registry lists them; a condition with its own page is linked.
early breast cancer, quality of life, skin condition